SCHEMBL24521555

SCHEMBL24521555

N[C@@H](Cc1ccc(O)cc1)C(=O)NCc1cccc(C(F)(F)F)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 1/20 0.53
TRPV1 Q8NER1 1/20 0.53
MLYCD O95822 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
PLA2G1B P04054 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C19 P33261 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ATG4B Q9Y4P1 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.47
FFAR1 O14842 1/20 0.47
FFAR4 Q5NUL3 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
HTR2B P41595 1/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27134423 1.00 OPRK1 (0.53) OPRK1TRPV1MLYCDMEN1KMT2A
SCHEMBL29052274 0.86 MTOR (0.58) TRPV1
SCHEMBL24521505 0.86 MTOR (0.58) TRPV1
SCHEMBL3153097 0.81 F2 (0.49) TRPV1MLYCDMEN1KMT2APLA2G1B
SCHEMBL15244590 0.80 HTR2A (0.55) OPRK1MLYCDMEN1KMT2APLA2G1B
SCHEMBL6173159 0.80 HTR2A (0.57) MLYCDMEN1KMT2APLA2G1BCYP1A2
SCHEMBL15244824 0.78 HTR2A (0.56) OPRK1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL23598418 0.78 MLYCD (0.45) OPRK1MLYCDMEN1KMT2APLA2G1B
SCHEMBL21794931 0.78 MLYCD (0.45) OPRK1MLYCDMEN1KMT2APLA2G1B
SCHEMBL21794928 0.78 NLN (0.66)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043374-A1 N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2024-02-08 US disclosed
CN-116583497-A N-benzyl-alpha-aminoamides as late promoting complex/loop (APC/C) inhibitors 科学研究高级委员会(CSIC) 2023-08-11 CN disclosed
WO-2022129397-A1 N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2022-06-23 WO disclosed
EP-4015501-A1 N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2022-06-22 EP disclosed
EP-4015501-A1 N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2022-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240043374-A1 N-BENZYL-ALPHA-AMINOAMIDES AS ANAPHASE-PROMOTING COMPLEX/CYCLOSOME (APC/C) INHIBITORS CCNI, CDC20, CCNB1 OPRK1 4555/4885TRPV1 4635/4885MLYCD 2987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.